Calithera Biosciences (CALA) News Today $0.0001 0.00 (-83.33%) (As of 12/20/2024 03:31 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.comDecember 18, 2024 | americanbankingnews.comCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comPrimecap Management Portfolio Exposed: Top Holdings RevealedApril 26, 2024 | msn.comArcus Biosciences Inc (RCUS)February 24, 2024 | uk.investing.comChristina CalaAugust 12, 2023 | npr.orgCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.June 1, 2023 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 20, 2023 | finanznachrichten.deCala MarioluMay 19, 2023 | travel.usnews.comCalithera Biosciences plans special meeting to seek approval for liquidation and dissolution planMay 19, 2023 | seekingalpha.comCalithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 19, 2023 | finance.yahoo.comCala LlombardsMay 13, 2023 | travel.usnews.comCalithera Biosciences Inc (CALA) Earnings Dates & ReportsMay 12, 2023 | investing.comCalithera Biosciences Shares Plummet on Liquidation Plans >CALAJanuary 11, 2023 | marketwatch.comCalithera Biosciences to Liquidate >CALAJanuary 11, 2023 | marketwatch.comBiotech company Calithera plans its own death. Will others follow?January 10, 2023 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionJanuary 9, 2023 | finanznachrichten.deCalithera Biosciences Board Of Directors Determine Dissolution Of CompanyJanuary 9, 2023 | markets.businessinsider.comCalithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionJanuary 9, 2023 | finance.yahoo.comTrading was temporarily halted for "CALA" at 07:01 AM with a stated reason of "News pending."January 9, 2023 | marketbeat.comCalithera Biosciences, Inc.: Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | seekingalpha.comCalithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | finance.yahoo.comCalithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022November 8, 2022 | finance.yahoo.comCalithera Biosciences Gets FDA Fast Track For Lung Cancer DrugOctober 3, 2022 | marketwatch.comCalithera Gets FDA Fast Track Designation For Sapanisertib For Squamous Lung Cancer TreatmentOctober 3, 2022 | nasdaq.comCalithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung CancerOctober 3, 2022 | finance.yahoo.comCalithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidateOctober 3, 2022 | finance.yahoo.comCALA Calithera Biosciences, Inc.October 1, 2022 | seekingalpha.comCalithera Biosciences IncSeptember 21, 2022 | reuters.com3 Penny Stocks With Surprisingly Superior FundamentalsSeptember 17, 2022 | finance.yahoo.comCalithera to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | finance.yahoo.comCompanies Like Calithera Biosciences (NASDAQ:CALA) Could Be Quite RiskyAugust 16, 2022 | finance.yahoo.comCalithera Biosciences Reports Second Quarter 2022 Financial Results and Recent HighlightsAugust 16, 2022 | finance.yahoo.comCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call TranscriptAugust 16, 2022 | seekingalpha.comEarnings Preview For Calithera BiosciencesAugust 12, 2022 | msn.comCalithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022August 8, 2022 | finance.yahoo.comCalithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma ConferencesJuly 13, 2022 | apnews.comCalithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma ConferencesJuly 13, 2022 | finance.yahoo.comCalithera Biosciences Announces First Patient Enrolled in PhaseJuly 6, 2022 | tmcnet.comCalithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung CancerJuly 6, 2022 | finance.yahoo.comWhat is a Reverse Stock Split and How Does it Work?July 5, 2022 | finance.yahoo.comCalithera Commences Mid-Stage Study Of DLBCL CandidateJune 23, 2022 | benzinga.comCalithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell LymphomaJune 23, 2022 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces 1-for-20 Reverse Stock SplitJune 15, 2022 | finanznachrichten.deCalithera Biosciences announces 1-for-20 reverse stock split to regain listing complianceJune 14, 2022 | seekingalpha.comCalithera Biosciences Announces 1-for-20 Reverse Stock SplitJune 14, 2022 | finance.yahoo.comAfter a record-breaking decade, biotech is discovering what hard times feel likeMay 27, 2022 | finance.yahoo.comCalithera to Present at the H.C. Wainwright Global Investment ConferenceMay 17, 2022 | finance.yahoo.com Get Calithera Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW CALA Media Mentions By Week CALA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CALA News Sentiment▼0.000.60▲Average Medical News Sentiment CALA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CALA Articles This Week▼10▲CALA Articles Average Week Get Calithera Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMPE News Today EFTR News Today ALVO News Today BCTXW News Today FBIOP News Today GOVXW News Today PHVS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CALA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
